BofA upgraded Integer (ITGR) to Buy from Neutral with a price target of $135, up from $105. Integer should benefit from the emergence of pulsed field ablation, or PFA, to treat atrial fibrillation as a key component supplier for major PFA devices sold by Boston Scientific (BSX), Medtronic (MDT) and Johnson & Johnson (JNJ), the analyst tells investors. The firm expects upcoming PFA device launches could add as much as $90M of incremental revenue for Integer in 2025, the analyst added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ITGR:
